BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 17027282)

  • 1. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
    Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
    Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
    Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
    Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.
    Jørgensen TJ; Gårdsvoll H; Danø K; Roepstorff P; Ploug M
    Biochemistry; 2004 Nov; 43(47):15044-57. PubMed ID: 15554712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
    Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
    Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
    Engelholm LH; Behrendt N
    Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
    Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
    J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
    Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
    Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
    Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
    Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
    Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
    Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling.
    Behrendt N
    Biol Chem; 2004 Feb; 385(2):103-36. PubMed ID: 15101555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.
    Hansen LV; Gårdsvoll H; Nielsen BS; Lund LR; Danø K; Jensen ON; Ploug M
    Biochem J; 2004 Jun; 380(Pt 3):845-57. PubMed ID: 15012588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.